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Abstract
This study compares the performance of four commercial multiplex PCR assays (Resplex II Panel v2.0, Seeplex RV15, xTAG RVP and
xTAG RVP Fast) and direct ﬂuorescent antibody (DFA) staining and viral isolation. Seven hundred and ﬁfty nasopharyngeal swabs were
tested for 17 viral agents. In each assay, the sensitivity and speciﬁcity for each target were determined against a composite reference
standard. Two hundred and eighty-eight out of 750 (38.4%) specimens were positive by DFA or viral isolation, while an additional 214
(28.5%) were positive by multiplex PCR, for a total positivity rate of 66.9%. Of 502 positive specimens, one virus was detected in 420
specimens (83.7%), two in 77 (15.3%), three in four (0.8%) and four in one case (0.2%). Compared with a composite reference standard,
the inter-assay accuracy of the multiplex PCR assays varied, but all were superior to conventional diagnostic methods in detecting a
broad range of respiratory viral agents in children. In addition, the sensitivity of two commercial assays, Resplex II Plus PRE and Seeplex
Inﬂuenza A/B Subtyping, was determined relative to the Astra inﬂuenza Screen & Type assay for detection of inﬂuenza A viruses, includ-
ing seasonal inﬂuenzas and pandemic H1N1 2009 inﬂuenza A virus. Using 75 positive and 55 negative nasopharyngeal swabs for inﬂuenza
A by the Astra assay, the sensitivity of Seeplex and Resplex was 95.9% and 91.8%, respectively, with a speciﬁcity of 100% for both.
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Introduction
Acute viral respiratory tract infections are a signiﬁcant cause
of morbidity and mortality in children, particularly those with
compromised immune systems [1–3]. Nucleic acid ampliﬁca-
tion tests have shown their superiority over classical diagnos-
tic methods, such as direct ﬂuorescent antibody detection
(DFA) and viral isolation, in identifying a broader range of
viruses, with higher sensitivity and speciﬁcity [4–6]. Recently,
several studies have demonstrated the advantages of multi-
plex PCR for simultaneous detection of a panel of viruses in
one assay [7–14]. In this study we compared (i) the sensitivity
and speciﬁcity of four commercial multiplex PCR assays with
DFA and viral isolation for detection of respiratory viruses in
children, and (ii) the sensitivity of two assays, Resplex II Plus
PRE and Seeplex Inﬂuenza A/B Subtyping, with the Astra inﬂu-
enza Screen & Type assay and DFA for detection of H1 and
H3 seasonal and pandemic H1N1 2009 inﬂuenza A virus.
Materials and Methods
Specimens
Multiplex assays. Seven hundred and ﬁfty nasopharyngeal
(NP) swabs were selected from children (birth to 17 years)
with suspected respiratory tract infection seen at The Hospi-
tal for Sick Children (Toronto, Canada). The ﬁrst 25 speci-
mens received each week for a 24-week period (November
2007 to April 2008), were selected, for a total of 600 specimens,
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without knowing results of DFA or viral isolation. An addi-
tional 150 specimens were chosen in the same manner (Janu-
ary 2009 to March 2009). Nasopharyngeal swabs (ﬂocked
swabs; COPAN Diagnostics, Murrieta, CA, USA) were inocu-
lated into 3 mL of Universal Transport Medium (UTM-RT
COPAN Diagnostics, Murrieta, CA, USA). After vortexing,
specimens from 2007/2008 (n = 600) were dispensed into
four 400-lL aliquots and stored at )80C until nucleic acid
extraction, whereas specimens from 2009 (n = 150) were
submitted to nucleic acid extraction before aliquoting and
freezing at )80C.
Specimen selection for comparison of assays to detect seasonal
inﬂuenza A and pandemic H1N1 2009 inﬂuenza. A total of
130 NP swab specimens were selected from aliquots of the
original specimens frozen at )80C on receipt: 75 inﬂuenza
A positive specimens by Astra Screen and Type assay (13
seasonal inﬂuenza A (INFA)-H1, 12 INFA-H3 and 50 pan-
demic H1N1 2009 inﬂuenza A (INFA)-H1N1), and 55 inﬂu-
enza A/B negative specimens by the Astra assay. All
specimens were made anonymous and de-linked from all
personal health identiﬁers.
DFA
DFA was performed using ﬂuorophore-labelled mono-
clonal antibodies against respiratory syncytial virus (RSV),
parainﬂuenza viruses 1–3 (PIV), adenovirus (ADV), INFA/B
(SimulFluor; Millipore, Temecula, CA, USA) and human
metapneumovirus (hMPV) (Diagnostic HYBRIDS, Athens, OH,
USA). DFA was carried out for each target as per the manu-
facturer’s protocol.
Cell culture
All NP swabs from 2007/2008 underwent both DFA and cul-
ture. During the 2009 pandemic, specimens that were posi-
tive for INFA by DFA were not cultured. Specimens were
inoculated in duplicate into R-Mix (Diagnostic HYBRIDS)
shell vials as per the manufacturer’s instructions. A shell vial
coverslip was stained with SimulFluor Respiratory Screen
Reagents (Millipore) containing monoclonal antibodies for
ADV, PIV 1–3, INFA/B and RSV as per the manufacturer’s
instructions. Staining for anti-hMPV was carried out using a
separate shell vial coverslip and reagents (Diagnostic
HYBRIDS) as per the manufacturer’s instructions.
Nucleic acid extraction
Nucleic acid was extracted from 400 lL of specimen using
the biorobot M48 workstation/MagAttract Virus Mini M48
kit (Qiagen, Mississauga, ON, Canada) and eluted in 100 lL
of elution buffer.
Multiplex RT-PCR
Respiratory viral panels. The extracted nucleic acid was
ampliﬁed by four commercial multiplex assays: Resplex II Panel
v2.0 (Qiagen), Seeplex RV15 (Seegene Inc., Seoul, Korea),
xTAG Respiratory Viral Panel (RVP) and xTAG RVP Fast
(Luminex Molecular Diagnostics, Toronto, ON, Canada).
cDNA and ampliﬁcation steps were carried out in a single-tube
format for Resplex II v2.0, RVP and Fast assays whereas See-
plex RV15 required a separate cDNA synthesis step using a
RevertAid H Minus First Strand cDNA Synthesis kit (Fermen-
tas, Burlington, ON, Canada) before performing the multiplex
PCR step.
Ampliﬁcation products were detected using the LiquiChip
200 (Luminex 200) (Austin, TX, USA) for Resplex II v2.0,
and the Luminex 100 for RVP and RVP Fast. Qiagen instructs
each user to determine appropriate cut-off values for their
testing platform and patient population. Cut-off values for
Resplex II v2.0 were determined empirically to be the sum
of the mean MFI plus ‡5 times the standard deviation of neg-
ative specimens (negative in all assays). The cut-off values for
RVP and RVP Fast were predetermined by the manufacturer.
Each assay had an internal control (IC) included to rule out
PCR inhibition. Table 1 shows the targets and characteristics
of each multiplex assay.
To detect ampliﬁcation products, the Seeplex RV15 assay
was coupled with capillary electrophoresis technology
(Lab901Screen Tape system; Lab901 Ltd, Loanhead, UK).
Speciﬁc detection of seasonal inﬂuenza A and pandemic H1N1
2009 inﬂuenza A virus. Ampliﬁcation from a selected sub-
population of specimens was performed using the Astra
inﬂuenza Screen and Type (Astra Diagnostics, Hamburg,
Germany), Resplex II Plus Panel PRE (Qiagen) and Seeplex
Inﬂuenza A/B Subtyping (Seegene) assays. The Astra inﬂuenza
Screen & Type triplex assay was designed to detect seasonal
INFA and pandemic H1N1 2009 INFA in a real-time RT-PCR
format and used the Rotor-Gene 3000 instrument (Corbett
Research, Mortlake, NSW, Australia). This assay was chosen
as the reference standard due to its performance in a proﬁ-
ciency panel for the detection of H1N1 2009 INFA, in which
22 laboratories participated, using 18 different assays. The
Astra kit was found to have the highest sensitivity of detec-
tion compared with all other assays, including the CDC
H1N1 2009 assay (26th Annual Clinical Virology Symposium,
abstract S35). Specimens were also tested by the Resplex II
Plus Panel PRE (same targets as Resplex II Panel v2.0 plus
pandemic H1N1 2009 INFA) and the Seeplex Inﬂuenza A/B
Subtyping assay (INFA, INFA-H1, pandemic H1N1 2009
INFA, INFA-H3 and INFB). Amplicons from the Resplex II
Plus Panel PRE and Seeplex Inﬂuenza A/B Subtyping assays
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were detected using the LiquiChip 200 and the MultiNA
instrument, a microchip electrophoresis system for DNA/
RNA analysis (Shimadzu Biotech, Tokyo, Japan), respectively.
Each assay had an IC to detect inhibition of ampliﬁcation.
Ethics
This study was approved by the Research Ethics Board of
the Hospital for Sick Children.
Deﬁnitions
True positive. For all targets except PIV4, BoV, coronavi-
ruses, enterovirus and rhinovirus, any positive viral culture
or a positive result for a single target from any two of DFA
and the four molecular assays was considered true positive.
Because PIV4, BoV, coronaviruses, enterovirus and rhino-
virus could not be detected by DFA or viral isolation, a true
positive for these agents was deﬁned as a positive result in
at least two of the three or four multiplex PCR assays.
False positive. A single positive result in any assay, with the
exception of viral culture, was considered false positive.
Results
Respiratory viral panels
Distribution of respiratory viruses. Virus isolation was per-
formed on 684 specimens. Of 750 specimens tested, 502
(66.9%) were considered true positive results for at least
one virus by DFA, culture or PCR; 288/750 (38.4%) speci-
mens were positive by DFA or viral isolation, while an
additional 214 (28.5%) were positive by multiplex PCR. A
single virus was detected in 420 specimens (83.7%), two
viruses in 77 (15.3%), three in four specimens (0.8%)
and four viruses in one (0.2%). Table 2 shows the overall
distribution of respiratory viral pathogens, indicating the
predominance of enteroviruses/rhinoviruses, inﬂuenza
viruses and RSV. It also shows that parainﬂuenza viruses,
hMPV and coronaviruses accounted for about 7% each, fol-
lowed by bocavirus and adenovirus at around 4% each.
Among dual infections (n = 77) entero/rhinoviruses were
most commonly associated with other viruses. Triple virus-
infected specimens included ADV + enterovirus/rhino-
virus + BoV (n = 1), PIV4 + ADV + enterovirus/rhinovirus
(n = 1), RSVB + NL63 + BoV (n = 1) and RSVB + PIV4 +
enterovirus/rhinovirus (n = 1). The unique quadruple-agent
infected specimen was PIV3 + NL63 + enterovirus/rhinovirus +
BoV (n = 1).
Comparison of sensitivity and speciﬁcity among assays. Sensi-
tivity and speciﬁcity were calculated for each target and
TABLE 1. Targets and characteristics of multiplex assays for detection of respiratory viruses
Assay Resplex II v2.0 Seeplex RV15 xTAG RVP xTAG RVP Fast
Target Inﬂuenza A, B Inﬂuenza A, B Inﬂuenza A (H1, H3, H5), B Inﬂuenza A (H1, H3), B
Respiratory syncytial virus A, B Respiratory syncytial virus A, B Respiratory syncytial virus A, B Respiratory syncytial virus A, B
Parainﬂuenza 1–4 Parainﬂuenza 1–4 Parainﬂuenza 1–4 Parainﬂuenza 1–4
Human metapneumovirus Human metapneumovirus Human metapneumovirus Human metapneumovirus
Adenovirus B,E Adenovirus B,C,E, some A,D Adenovirus A–F Adenovirus A-F
Bocavirus Bocavirus – Bocavirus
Coronavirus OC43 Coronavirus OC43/HKU1 Coronavirus OC43 Coronavirus OC43
Coronavirus HKU1 Coronavirus HKU1 Coronavirus HKU1
Coronavirus 229E Coronavirus 229E/NL63 Coronavirus 229E Coronavirus 229E
Coronavirus NL63 Coronavirus NL63 Coronavirus NL63
– – SARS coronavirus –
Enterovirus Enterovirus Enterovirus/Rhinovirus Enterovirus/Rhinovirus
Rhinovirus Rhinovirus A/B/C
Technology End-point RT-PCR
Microsphere-based detection
End-point RT-PCR
Dual priming oligo (DPO)
End-point RT-PCR
Microsphere-based detection
End-point RT-PCR
Microsphere-based detection
Equipment LiquiChip (Luminex 200 system) Lab901 ScreenTape system Luminex 100 system Luminex 100 system
Ampliﬁcation/detectiona 310 min 520 min 450 min 220 min
aFor 24 specimens and excluding the nucleic acid extraction. Times are approximate.
TABLE 2. Distribution of respiratory viruses in paediatric
nasopharyngeal samples
Virus
Virus
subtype Number
Single-
infection
number (%)
Dual-
infection
number (%)
Enterovirus/
rhinovirus
– 173 128 (21.7) 45 (7.6)
RSV A 86 108 (18.3) 34 (5.8)
B 56
INFA H1 40 58 (9.74) 6 (1.02)
H3 22
Unidentiﬁed 2
INFB – 37 34 (5.8) 3 (0.51)
Parainﬂuenza 1 14 25 (4.23) 12 (2.04)
2 9
3 6
4 8
hMPV – 39 27 (4.6) 12 (2.0)
Coronavirus NL63 13 20 (3.28) 22 (3.69)
OC43 15
HKU1 12
229E 2
BoV – 21 7 (1.2) 14 (2.4)
ADV – 19 13 (2.2) 6 (1.0)
Total – 574 420 (71.2) 154 (26.1)
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assay according to our deﬁnition of a true and false
positive (Tables 3 and 4). Some viral targets were lumped
together as necessary to perform a sensitivity and speciﬁc-
ity analysis (i.e. entero/rhinovirus, coronaviruses). Table 3
indicates that DFA and culture were, as expected, less
sensitive than PCR for most targets. However, DFA was
more sensitive than PCR for a small number of speciﬁc
targets and assays (i.e. inﬂuenza B and parainﬂuenza 1–4
by RVP Fast and RSV A, B by Resplex, RVP and RVP
Fast).
Seeplex RV15 demonstrated sensitivity of ‡96.9% for all
targets except entero/rhinovirus (71.7%). Resplex II v2.0
had good sensitivity for inﬂuenza A and B (‡96.9%), but
lower sensitivity in the detection of hMPV, PIV and RSV
(82.0–84.0%). Resplex II v2.0 sensitivity fell further for ADV
and BoV (71.4% and 75.0%, respectively). RVP showed high
sensitivity for INFA/B and hMPV (‡98.4%), but lower
sensitivity for PIV, ADV and RSV (85.4–88.2%), and lowest
sensitivity for CoV OC43/HKU1 (48.1%). RVP Fast had
good sensitivity for INFA, hMPV, RSV, BoV and entero/rhi-
noviruses, but demonstrated signiﬁcantly reduced sensitivity
in the detection of ADV, CoV OC43/HKU1, INFB and PIV
(52.4–65.8%).
The speciﬁcity of DFA and the multiplex kits was generally
very high (Table 4), with all multiplex assays showing a speci-
ﬁcity of >98% for all targets except for RSV A/B for Seegene
(97.7%), entero/rhinovirus for RVP (96%) and parainﬂuenza
virus 1–4 (97.6%) for RVP Fast.
Comparison of commercial assays for the detection of sea-
sonal inﬂuenza A subtypes and pandemic H1N1 2009 inﬂu-
enza A virus
The Seeplex inﬂuenza A/B Subtyping and Resplex II Plus
Panel PRE assays showed good sensitivity (95.9% and 91.8%,
respectively) in detecting pandemic H1N1 2009 INFA com-
pared with the Astra inﬂuenza Screen & Type assay
(Table 5). Resplex II Plus Panel PRE and Seeplex inﬂuenza A/
B Subtyping assays detected all 25 seasonal INFA-H1 and
INFA-H3 positives, even though the Seeplex subtyping assay
was unable to subtype two INFA-H1 and one INFA-H3 posi-
tive specimens. Fifty-ﬁve negative specimens remained nega-
tive in all assays.
TABLE 3. Sensitivity of direct ﬂuorescent antibody (DFA), culture and four multiplex assays for detection and identiﬁcation of
respiratory viruses. Number of positives (within brackets)
Target DFA Culture Resplex II Panel v2.0 Seeplex RV15 xTAG RVP xTAG RVP Fast
INFA 76.7% (46) 60.3% (35) 96.9% (62) 96.9% (62) 98.4%a (63) 93.7%b (60)
INFB 78.4% (29) 75.0% (21) 100% (37) 100% (37) 100% (36) 64.9% (24)
PIV (1–4) 72.4% (21) 61.5% (16) 82.9% (34) 97.6% (40) 85.4% (35) 65.8% (26)
PIV1 76.9% 66.7% 86.7% 93.3% 71.4% 46.7%
PIV2 55.5% 44.4% 88.9% 100% 100% 77.8%
PIV3 100% 66.7% 100% 85.7% 71.4% 42.8%
PIV4 – – 60.0% 100% 100% 100%
hMPV 68.6% (24) 43.3% (13) 82.0% (32) 97.4% (38) 97.4% (38) 92.3% (36)
RSV (A/B) 93.5% (130) 86.5% (96) 84.0% (121) 100% (144) 88.2% (127) 91.7% (132)
RSVA – – 90.4% 100% 85.5% 92.5%
RSVB – – 79.3% 100% 98.3% 94.8%
ADV 38.1% (8) 44.4% (8) 71.4% (15) 100% (21) 85.7% (18) 52.4% (11)
BoV – – 75.0% (18) 100% (24) – 100% (24)
CoV OC43/HKU1 – – 92.6% (25) 100% (27) 48.1% (13) 59.3% (16)
CoV 229E/NL63 – – 100% (17) 100% (17) 88.2% (15) 88.2% (15)
Enterovirus/rhinovirus – – 96.7% (172) 71.7% (127) 93.8% (167) 97.7% (174)
aBased on combination of INFA + H1 + H3 + H5.
bBased on combination of INFA + H1 + H3.
TABLE 4. Speciﬁcity of direct ﬂuorescent antibody (DFA), culture and four multiplex assays for detection and identiﬁcation of
respiratory viruses
Target DFA (%) Culture (%) Resplex II
Panel v2.0 (%)
Seeplex RV15 (%) xTAG RVP (%) xTAG RVP Fast (%)
INFA 99.7 100 100 98.8 100 100
INFB 99.8 100 100 100 100 100
PIV (1–4) 99.8 100 100 99.0 99.6 97.6
hMPV 99.4 100 100 99.7 99.7 100
RSV (A/B) 99.6 100 100 97.7 100 100
ADV 100 100 99.9 98.1 99.9 100
BoV – – 100 100 – 99.6
CoV OC43/HKU1 – – 100 99.3 99.9 100
CoV 229E/NL63 – – 100 98.8 99.9 100
Entero/rhinovirus – – 99.3 99.1 96.0 99.8
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Discussion
In a head to head comparison of four multiplex PCR assays
with DFA and culture in children, multiplex PCR offered sig-
niﬁcantly improved sensitivity in the detection of the tradi-
tionally diagnosed respiratory viral agents (INFA, INFB, PIV
(1–3), RSVA, RSVB, ADV and hMV), in addition to detecting
coronaviruses, BoV, enteroviruses and rhinoviruses, which
increased the overall positivity rate from 38.4% to 66.9%.
Among all the multiplex assays tested, Seeplex RV15 was
the most sensitive for detecting all targets except for entero-
viruses and rhinoviruses. All multiplex assays had good sensi-
tivity for the detection of inﬂuenza A (93.7–98.4%). Inﬂuenza
B sensitivity was good in all multiplex assays (100%) except
for RVP Fast (64.9%). The superior performance of Seeplex
RV15 for RSV (100% sensitivity) reﬂected strong perfor-
mance for both RSVA and RSVB, whereas the decreased
sensitivity of other assays reﬂected a weaker performance
for either target (i.e. Resplex II v2.0: RSVA 90.4%, RSVB
79.3%, and RVP: RSVA 85.5%, RSVB 98.3%). Similarly, vari-
ability in the sensitivity of individual targets of the four para-
inﬂuenza viruses resulted in variation in the overall
sensitivity. Again, Seeplex RV15 showed good sensitivity for
all four types (85.7–100%), while Resplex II v2.0 had reduced
sensitivity for PIV4 (60%), RVP had reduced sensitivity for
PIV1 (71.4%) and 3 (71.4%), and RVP Fast had reduced sensi-
tivity for PIV1 (46.7%), 2 (77.8%) and 3 (42.8%). Sensitivity
for detecting hMPV was good for Seeplex RV15, RVP and
RVP Fast (92.3–97.4%), and acceptable for Resplex II v2.0
(82%). However, performance for adenovirus, an important
respiratory pathogen, was very variable, ranging from 52.4%
(RVP Fast) to 100% (Seeplex RV15), probably reﬂecting the
variation in serotype coverage among the assays.
Of the additional viral agents tested in the multiplex
assays, the coronaviruses were consistently detected across
all assays except for CoV OC43 by RVP (53.8%) and CoV
HKU1 by RVP Fast (16.7%). Seeplex RV15 and RVP Fast
detected 100% of bocavirus infections, while the sensitivity
of Resplex II v2.0 was only 75%. Detection of enterovirus
and rhinovirus was the most inconsistent. Although the
speciﬁc targets for each multiplex assay are proprietary, it
is known that the highly conserved regions of the 5¢NTR
region of either rhinoviruses or enteroviruses, will also
amplify members of the other genus. Thus, some assays,
such as the RVP and RVP Fast assays, have combined the
enterovirus and rhinovirus targets, because developing spe-
ciﬁc targets for each genus outside of the 5¢NTR region
may compromise sensitivity of detection, especially of the
rhinoviruses. This is possibly the case with the Seeplex
RV15 assay, which separates enteroviruses and rhinoviruses,
but has a lower sensitivity than the other assays. Though
the Resplex II v2.0 assay differentiates between entero-
viruses and rhinoviruses, the occurrence of 38.4% of posi-
tive specimens testing positive for both targets, suggests
that there may be cross-reactivity between them.
Speciﬁcity was excellent for all assays, using our compos-
ite reference standard. Without using individual single-plex
assays to adjudicate the single test positives, we cannot
determine whether the slightly lower speciﬁcity observed for
a few targets in several assays was due to higher sensitivity
of detection or detection of false positives.
Multiplexed respiratory panels provide clinicians with
more diagnostic and treatment information for managing
patients. In the case of inﬂuenza A, knowledge of the subtype
is important with respect to predicting the activity of anti-
viral agents such as the adamantanes and neuraminidase
inhibitors. In addition to increased sensitivity and number of
viruses detected, multiplex assays permit the improved iden-
tiﬁcation of cases of infection with multiple agents, which
may be clinically signiﬁcant, especially in immune compro-
mised individuals. In our study, we found that two or more
viruses were present in 10.9% of specimens (16.3% of posi-
tive specimens). Bocavirus and coronaviruses were the
viruses most commonly associated with multiple agent infec-
tion, followed by human metapneumovirus, the parainﬂuenza
viruses, adenovirus and the entero/rhinoviruses. Inﬂuenza
A/B and RSV were the least likely to be detected in the
TABLE 5. Performance of two commercial multiplex PCR assays vs. Astra Inﬂuenza Screen and Type assay for detection of
the pandemic H1N1 2009 inﬂuenza A virus and seasonal inﬂuenza A strains
Target Number
DFA #
(% positive)
Astra inﬂuenza
Screen & Type #
(% positive)
Resplex II
Plus Panel
PREa # (% positive)
Seeplex
inﬂuenza A/B
Subtyping
# (% positive)
Pandemic H1N1 2009 INFA 50 32/46 (69.6%) 50 (100%) 46 (92%) 48 (96%)
INFA (seasonal H1 and H3) 25 14 (56%) 25 (100%) 25 (100%) 25 (100%)
Seasonal H1N1 INFA 13 4/10 (40%) 13 (100%) 13 (100%) 11 (84.6%)
Seasonal H3N2 INFA 12 10 (83.3%) 12 (100%) 12 (100%) 11 (91.7%)
Negative 55 0 0 0 0
aResplex II Plus Panel PRE assay does not differentiate INFA subtypes (except for pandemic H1N1 2009 inﬂuenza A subtype).
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presence of another virus. The role of multiple viral agents
in affecting the clinical course of disease is at present
unknown and worthy of further study.
With respect to the technical performance of the different
multiplex assays, the following issues were identiﬁed: Seeplex
RV15 was designed as a two-step RT-PCR format necessitat-
ing a separate RT (cDNA) assay, though a new one-step pro-
cedure has been developed. It was the only assay that
required three PCR master mixes with ﬁve targets in each
one plus the internal control. It was also the only assay that
incorporated positive controls for all 15 viral targets, which
is considered an additional quality control feature of the
assay. Seeplex RV15 was the assay with the shortest post-
PCR step, especially for a small number of specimens when
using the Lab 901 Screen Tape system (maximum ﬁve spec-
imens per run). In contrast, the Resplex II v2.0, RVP and
RVP Fast use a 96-well microtitre plate format on the Lum-
inex platform, permitting high throughput analysis.
Practical considerations in most laboratories regarding the
feasibility and the direct and indirect costs of introducing
multiplex molecular testing for respiratory viruses have led
to a relatively slow routine implementation of this methodol-
ogy. Mahony et al. [15] have shown that RVP employed as
the ﬁrst-line diagnostic tool in children was the least costly
strategy, compared with DFA and culture, DFA alone or
DFA plus RVP, when the prevalence of infection was ‡11%.
The cost of molecular testing is offset by its more efﬁcient
use of labour than conventional DFA and culture and by sav-
ings to the healthcare system when additional testing and
hospitalization can be avoided by knowledge of a test result
with high sensitivity and speciﬁcity. Operationally, molecular
methods also allow virology laboratories to continue to func-
tion, even in the event that viral culture cannot be carried
out due to biosafety issues.
In our study, newer assays or versions of the multiplex
assays (Resplex II Plus Panel PRE (21 targets) and Seeplex
Inﬂuenza A/B Subtyping (six targets)) showed good sensitivity
and speciﬁcity relative to a tri-plex inﬂuenza real-time RT-
PCR (Astra inﬂuenza Screen & Type) for pandemic H1N1
2009 INFA virus detection. This is important, as traditional
seasonal H1 subtyping molecular assays will not react with
the pandemic strain and it is expected that the 2009 pan-
demic strain may become the predominant circulating sea-
sonal H1 strain in the immediate post-pandemic period.
We have shown that multiplex PCR increases the sensitiv-
ity of detection of respiratory viruses in children by 74.3%
over DFA and viral isolation, while maintaining excellent spec-
iﬁcity. However, it will be important to develop more effec-
tive clinical and laboratory algorithms for their timely
and optimal use and to study their impact on patient care in
different populations in different clinical settings. Inﬂuenza,
RSV, parainﬂuenza virus, adenovirus and hMPV have been
well established as leading causes of respiratory infection
among infants and children [16–18]. However, the role of rhi-
noviruses, enteroviruses, bocavirus and coronaviruses as co-
pathogens in upper respiratory tract infection or as agents of
lower respiratory tract infection, has been less well investi-
gated, and will be aided by studies using this technology [19].
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